Market Sentiment Around Loss-Making Ardelyx, Inc. (NASDAQ:ARDX)
Market Sentiment Around Loss-Making Ardelyx, Inc. (NASDAQ:ARDX)
With the business potentially at an important milestone, we thought we'd take a closer look at Ardelyx, Inc.'s (NASDAQ:ARDX) future prospects. Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The US$1.4b market-cap company's loss lessened since it announced a US$66m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$65m, as it approaches breakeven. Many investors are wondering about the rate at which Ardelyx will turn a profit, with the big question being "when will the company breakeven?" Below we will provide a high-level summary of the industry analysts' expectations for the company.
由于该业务可能处于一个重要的里程碑,我们想仔细研究一下Ardelyx, Inc.”s(纳斯达克股票代码:ARDX)的未来前景。生物制药公司Ardelyx, Inc. 在美国和国际上发现、开发和商业化治疗胃肠道和心肾脏治疗领域的药物。自宣布全年亏损6600万美元以来,这家市值为14亿美元的公司亏损有所减少,而最近十二个月的亏损在接近盈亏平衡时为6500万美元。许多投资者想知道Ardelyx的盈利速度,最大的问题是 “公司何时会实现盈亏平衡?”下面,我们将概述行业分析师对公司的期望。
Consensus from 10 of the American Biotechs analysts is that Ardelyx is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$116m in 2026. So, the company is predicted to breakeven approximately 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 66% year-on-year, on average, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
10位美国生物技术分析师的共识是,Ardelyx处于盈亏平衡的边缘。他们预计,该公司将在2025年蒙受最终亏损,然后在2026年产生1.16亿美元的正利润。因此,预计该公司将在大约两年后实现盈亏平衡。为了在2026年之前达到盈亏平衡点,公司每年必须以多快的速度增长?从分析师的估计来看,事实证明,他们预计公司平均同比增长66%,这是相当乐观的!如果业务增长速度放缓,则盈利的时间将比预期的晚。
Underlying developments driving Ardelyx's growth isn't the focus of this broad overview, but, take into account that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
推动Ardelyx增长的潜在发展并不是本次广泛概述的重点,但要考虑到生物技术公司通常会有不规则的现金流,具体取决于产品开发阶段。因此,高增长率并非不寻常,尤其是在公司处于投资期时。
Before we wrap up, there's one issue worth mentioning. Ardelyx currently has a relatively high level of debt. Typically, debt shouldn't exceed 40% of your equity, which in Ardelyx's case is 84%. Note that a higher debt obligation increases the risk around investing in the loss-making company.
在我们总结之前,有一个问题值得一提。Ardelyx目前的债务水平相对较高。通常,债务不应超过您权益的40%,就Ardelyx而言,该比例为84%。请注意,更高的债务负债会增加投资这家亏损公司的风险。
Next Steps:
后续步骤:
There are too many aspects of Ardelyx to cover in one brief article, but the key fundamentals for the company can all be found in one place – Ardelyx's company page on Simply Wall St. We've also put together a list of essential aspects you should look at:
Ardelyx的很多方面都无法在一篇简短的文章中介绍,但是该公司的关键基础知识都可以在一个地方找到——Ardelyx在Simply Wall St的公司页面。我们还整理了一份你应该考虑的重要方面清单:
- Valuation: What is Ardelyx worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Ardelyx is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Ardelyx's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Ardelyx 今天的价值是多少?价格中是否已经考虑了未来的增长潜力?我们的免费研究报告中的内在价值信息图有助于可视化Ardelyx目前是否被市场定价错误。
- 管理团队:由经验丰富的管理团队掌舵增强了我们对业务的信心——看看谁是Ardelyx董事会成员以及首席执行官的背景。
- 其他表现优异的股票:还有其他股票可以提供更好的前景并有良好的往绩记录吗?在这里浏览我们免费列出的这些优质股票。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。